Cas9 Stable Cell Line - MG-63

The MG-63-Cas9 stable cell line is a specialized human genetic model derived from the MG-63 osteosarcoma cell line, genetically engineered to constitutively express the Cas9 nuclease. MG-63 is an adherent fibroblast-like cell line isolated from a 14-year-old male patient with osteosarcoma, one of the most common primary malignant bone tumors. These cells grow rapidly and are known for expressing multiple bone-specific markers and their responsiveness to hormone stimulation. Integrating Cas9 into this cell line provides a highly standardized and efficient platform for CRISPR-mediated gene editing in a bone-related context. This system ensures the consistency of genomic modifications across the entire cell population, overcomes the limitations of transient transfection, and provides a reliable tool for elucidating the complex genetic mechanisms of bone tumors and osteoblast differentiation.

The primary applications of the MG-63-Cas9 stable cell line are in studying osteosarcoma progression and developing strategies for bone tissue regeneration medicine. Scientists use this cell line for CRISPR screening to identify genes involved in tumor metastasis, drug resistance, and the regulation of bone remodeling and mineralization. It is a key model for studying osteogenic molecular pathways and identifying factors that promote the survival and proliferation of malignant bone cells. In the laboratory, the MG-63-Cas9 cell line has been used to construct targeted knockout models of various oncogenes and tumor suppressor genes, thereby gaining a deeper understanding of the pathways driving bone malignancies. Its well-defined phenotype and stable Cas9 expression make it an indispensable resource for basic orthopedic research and preclinical trials of novel invasive bone cancer therapies.